Congrats to Emily Lau, MD, MPH on the Zipes Distinguished Young Scientist Award at #ACC24

Great keynote talk on Overcoming the Male Bias: Why Sex Differences Matter

Today on #GoRedDay Michelle L O'Donoghue, MD, MPH, spoke with Boston 25 News about the different experiences and symptoms women have related to heart conditions. #HeartMonth boston25news.com/news/different…

TIMI Senior Investigator Michelle O'Donoghue joins Nicholas Marston and David Berg on the TIMI Talks Podcast to discuss Lp(a) therapies and the Ocean(a) trials. Listen now on all major podcast platforms!
podcasts.apple.com/us/podcast/tim…
open.spotify.com/show/38F4RGeb3…
podcasts.google.com/search/TIMI%20…

🆕 Women are Not Little Men hosted by Drs. Emily Lau, MD, MPH & Niti R. Aggarwal, MD, FSCMR, FASNC, FACC

Episode 3️⃣: Underrepresentation of Women in Clinical Research & Trials

Drs. Leslie Cho & Michelle O'Donoghue talk landscape of sex & gender representation in CV clinical research & trials. bit.ly/3pgtuQ3

I’m looking forward to this terrific conversation with Jim Spellos. Join us Thursday night for this livestream!

Today is Lipoprotein(a) Awareness Day! Raise awareness about this inherited disorder & make a difference for those who might not know about this common genetic condition #KnowLpa Family Heart Foundation Foundation of the NLA
Get more info at learnyourlipids.com & familyheart.org

Pregnancy not only reveals a woman's future CV risk but can also cause changes at the endothelial level that increase that risk. Cardiologists Michelle O'Donoghue and Rachel M Bond, MD discuss the issues. #CardioTwitter #ObGynTwitter ms.spr.ly/60185Czs8

What are the top 10 research lessons learned from TIMI in 2022? Find out at timi.org/top-timi-lesso…
Ben Scirica Erin Bohula Robert Giugliano Stephen Wiviott Michelle O'Donoghue Brian Bergmark David Berg Nicholas Marston André Zimerman Filipe A Moura, MD, PhD Prakriti Gaba Sid M. Patel

Rigorous #FOURIER event adjudication explained - misguided & uninformed attacks refuted!
timi.org/bmjopenrespons…

With targeted therapies on the horizon Michelle O'Donoghue & Steve Nicholls discuss Lp(a) and its role in #ASCVD #AHA22 ms.spr.ly/6010eD8Zo

.Michelle O'Donoghue and interventional cardiologists Rasha Al-Lamee & Jacqueline Tamis-Holland revisit whether patients with stable CAD are treated differently on the 3 year anniversary of the ISCHEMIA trial #AHA22 ms.spr.ly/6016dNhYA

Thank you to CardioNerds & Radcliffe Cardiology for the opportunity to interview trialists of late breaking trials at #AHA22

So great to talk with Michelle O'Donoghue about the OCEAN(a)-DOSE trial of olpasiran to reduce Lp(a) TIMI Study Group

🔗 bit.ly/3U6PjeV

We haven't had a treatment for Lp(a), a well known risk factor for heart disease. We may now. nejm.org/doi/full/10.10… #AHA2022 NEJM Michelle O'Donoghue
Marc Sabatine TIMI Study Group @Brighamw

Meet the Women in Cardiovascular Medicine! Today we celebrated recent promotions, awards, honors and many other accomplishments. Thank you Michelle O’ Donoghue, Sharmila Dorbala, Samia Mora and Anne Valente for your motivational words. Brigham and Women's Hospital⁩ cvls.bwh.harvard.edu/women-in-cardi…

I think it’s fascinating to watch how the CV mortality benefit develops over time!

Open Access: Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). pubmed.ncbi.nlm.nih.gov/35588897/

#Cardiotwitter #Cardiology Michelle O'Donoghue

🩺Join Michelle O'Donoghue in this short interview (from #ESC Congress2022 ) as she summarises the FOURIER-OLE trial design, highlighting the key results.

ow.ly/CFAZ50KGN8t

Intended for US-based physicians only.

#Cardiology #CardioTwitter #CardioNerds #ESC

Open access to phase 2 design of OCEAN(a) DOSE, siRNA that interferes with Lp(a) synthesis to markedly lower levels.

Can we really still justify aspirin as our choice for monotherapy? Marco Valgimigli